Closing Bell Spotlight: Momentum Names from Yesterday Continue to Roar

October 8, 2025

DENVER, Colo., Oct 08, 2025 (247marketnews.com)- It’s almost Power‑Hour time and biotech plays, several names that topped yesterday’s watchlist, continue to light up the tape.

NUBURU (NYSE:BURU) continues to ride its transformation narrative. Recently, the company priced a $12M public offering to fuel its pivot into defense tech and resilience software.

The strategic goal: hybridize its blue laser IP with defense verticals via acquisitions (Tekne S.p.A., Orbit S.r.l.), aiming to build a “Defense & Security Hub.”

Kraig Biocraft Laboratories (OTCQB:KBLB) is drawing heavy attention today, and for good reason. The company announced a new push for a third rearing facility, stating it expects to finalize a site within 60 days, a move to further scale its recombinant spider silk production.

The core narrative remains: by genetically engineering silkworms to spin spider silk, Kraig claims to have cracked what was long deemed a “centuries old problem”, spiders simply won’t farm easily. That gives KBLB a storyline of disruptive materials, with potential applications across biomedical, defense, and advanced textiles.

Kraig Labs is well positioned to potentially dominate several of what many experts project will be $multi-billion markets.

Nexalin Technology (NASDAQ:NXL) is seeing a sizzling breakout today after the company published positive clinical data showing its 15 milliamp Gen‑2 brain stimulation tech yielded statistically significant cognitive improvements in mild Alzheimer’s disease patients.

This clinical data narrative is fresh and powerful, when biotechs publish credible human data, the upside reaction can be dramatic. The stock is already spiking pre‑market, so into the close, look for continuation, especially if volume confirms.

Adaptimmune Therapeutics (NASDAQ:ADAP) is in the spotlight again. Recall that the company struck a $55M upfront licensing deal with US WorldMeds to sell therapies including TECELRA, lete‑cel, afami‑cel, and uza‑cel, plus up to $30M in future milestones.

Still, ADAP carries structural risk: it currently holds an exception period until December 1, 2025, to regain compliance with Nasdaq’s $1.00 bid rule.

Processa Pharmaceuticals (NASDAQ:PCSA) quietly closed a $5M public offering earlier this year with participation from the CEO and institutional investors. While not seeing headline catalysts today, PCSA may be playing as a volatility catch candidate, traders might be speculating on pipeline moves or regulatory news.

GT Biopharma (NASDAQ:GTBP) is drawing attention as it advances its TriKE NK cell engager platform, particularly with its lead asset GTB-3650 targeting CD33-positive leukemias. The company recently received FDA clearance for GTB-3650’s IND application and has entered into a clinical trial agreement with the University of Minnesota.

bioAffinity Technologies (NASDAQ:BIAF) is a diagnostics and therapeutics developer riding increased attention thanks to its CyPath Lung test, which posted nearly 100% sequential growth in test volume last quarter and is making inroads with adoption at Veterans Affairs hospitals and regional providers.

For more information about Kraig Labs’ spider silk technology and partnership opportunities, visit www.kraiglabs.com

Please click here to read the full Kraig Labs analyst report on 247marketnews.com.

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) is a biotechnology company focused on the development and commercialization of spider silk-based fiber technologies. Through its proprietary silkworm-based genetic engineering platform, Kraig Labs produces high-performance, cost-effective, and scalable spider silk materials for use in defense, performance apparel, technical textiles, and medical applications.

For more information, please visit: www.kraiglabs.com

Contact sales@247marketnews.com for Analyst Report coverage and other investor/public relations services.

PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 247 is a third-party media provider and has been compensated by one or more featured companies for providing ongoing KBLB market outreach and other services.. This press release may include technical analysis and should not be construed as financial or investment advice. Trading stocks involves risks, and readers should consult with their financial advisor before making investment decisions. Please review 247’s Full Disclaimer https://www.247marketnews.com/disclaimer/. Please go to https://247marketnews.com/kblb-disclosure/ for further KBLB and 247marketnews.com disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (BURU, KBLB, NXL, BIAF, ADAP, PCSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.